儿童中度持续性哮喘临床治疗的疗效观察

The observation of clinic treatment of children with moderate persistent asthma

目的在对中度持续性哮喘的治疗中比较各治疗方案间的疗效差异。方法将105名中度持续性哮喘患儿随机分为三组,分别给予吸入激素(ICS)+抗白三烯(LTRA)、ICS+长效β-2受体激动剂(LABA)、ICS+LABA+LTRA治疗。经过在3个月的治疗比较各治疗方案控制等级、有症状人数及肺功能(第一秒呼气容积占预计值百分比-FEV1%、呼气峰流速占预计值百分比-PEF、FEF25、FEF50、FEF75)改善情况。结果经过3个月的治疗,ICS+LABA+LTRA和ICS+LABA组各观察指标均较ICS+LTRA组好(P<0.05),其中前者对于改善小气道功能效果最好。结论对于中度持续性哮喘ICS联合LABA治疗优于ICS联合LTRA治疗,其中三者联合疗效最好,提示对于中度持续性哮喘ICS+LABA疗效欠佳时可加用LTRA治疗。

Objective To compare the efficacy in treatment of moderate persistent asthma. Methods 105 children with moderate persistent asthma were randomly divided into three groups, were separately given inhaled corticosteroid （ICS） ＋ Anti-leukotrienes （LTRA）, ICS ＋ lang-aeting β2 agonists （EABA） , ICS ＋ LABA ＋ LTRA treatments. To compare the improve situation before and after treatment whleh including control levels, the number of children with symptoms and lung function. Results After 3 months of treatment, the outcome measures of ICS ＋ LABA ＋ LTRA and ICS ＋ LABA group were observed better than ICS ＋ LTRA group （P〈0.05）, and the former was the best in improving small airway function. Conclusion Treat effects of ICS united LABA were better than united LTRA, the three united was the best. And it indicated that we could add LTRA when ICS ＋ LABA was not efficient for moderate persistent asthma.